Neutralizing monoclonal antibody care aids kidney transplant patients with omicron variant

Kidney transplant patients infected with COVID-19, including the omicron variant, benefit from neutralizing monoclonal antibody therapy, according to data published in Kidney Medicine.
“Neutralizing monoclonal antibody treatments have shown promising preliminary results in kidney transplant recipients with SARS-CoV-2,” Guillaume Fernandes, MD, from the division of nephrology of Cliniques Universitaires Saint-Luc at Université Catholique de Louvain in Belgium, and colleagues wrote. “However, its efficacy in kidney transplant recipients infected with the emerging omicron

Kidney transplant patients infected with COVID-19, including the omicron variant, benefit from neutralizing monoclonal antibody therapy, according to data published in Kidney Medicine.
“Neutralizing monoclonal antibody treatments have shown promising preliminary results in kidney transplant recipients with SARS-CoV-2,” Guillaume Fernandes, MD, from the division of nephrology of Cliniques Universitaires Saint-Luc at Université Catholique de Louvain in Belgium, and colleagues wrote. “However, its efficacy in kidney transplant recipients infected with the emerging omicron